Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $6.92.

CHRS has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Coherus BioSciences in a research report on Monday, September 16th. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Friday, September 6th. UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $4.00 to $1.50 in a report on Friday, August 16th. Finally, Robert W. Baird dropped their price target on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Monday, July 1st.

Read Our Latest Analysis on CHRS

Coherus BioSciences Stock Down 3.8 %

Shares of Coherus BioSciences stock opened at $1.00 on Thursday. The company has a market capitalization of $114.73 million, a price-to-earnings ratio of -1.28 and a beta of 0.65. The stock’s 50-day simple moving average is $1.24 and its 200-day simple moving average is $1.68. Coherus BioSciences has a 52 week low of $0.97 and a 52 week high of $3.98.

Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The business had revenue of $64.98 million during the quarter, compared to analysts’ expectations of $57.08 million. On average, equities analysts expect that Coherus BioSciences will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CHRS. Nisa Investment Advisors LLC increased its stake in Coherus BioSciences by 2,672.8% during the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 19,912 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Coherus BioSciences by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 21,426 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 8,546 shares during the period. Bayesian Capital Management LP purchased a new position in shares of Coherus BioSciences in the 1st quarter worth approximately $56,000. TIAA Trust National Association purchased a new stake in Coherus BioSciences during the 2nd quarter valued at $47,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Coherus BioSciences by 32.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock worth $74,000 after buying an additional 7,608 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Company Profile

(Get Free Report

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

Featured Stories